Brief: Orchard Therapeutics Presents Data Demonstrating Sustained Clinical Benefit Of OTL-200 For Treatment Of Metachromatic Leukodystrophy
04/09/2019 12:24
Sept 4 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS PRESENTS AN INTEGRATED DATA ANALYSIS
DEMONSTRATING SUSTAINED CLINICAL BENEFIT OF OTL-200 FOR THE
TREATMENT OF METACHROMATIC LEUKODYSTROPHY
Source text for Eikon: ID:nGNXkHC6N
Further company coverage: ORTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln